Suboptimal inhaler use: why are we still facing the same challenges?
Approximately 84.8 million people live with asthma and chronic obstructive pulmonary disease (COPD) in Europe1,2. These chronic respiratory diseases result in substantial clinical and economic burden3, with 9.7 million healthy years lost annually1,2. The majority of these patients have inadequately managed disease4,5, which often reflects poor inhaler adherence and technique6–10. Good inhaler use is important as poor inhaler mastery is associated with increased morbidity and hospitalisations11. As healthcare professional- and self-assessed inhaler use may not reflect real-life scenarios12, it is important that accurate means of measuring patients’ inhaler adherence and technique are developed to improve disease management.
To learn more about unmet needs in asthma and COPD, see the animation below.
Let’s Talk Respiratory is organised and funded by Teva Pharmaceuticals and intended for healthcare professionals only. Information in the video/article may discuss drug classes where Teva have a product or products that are not authorised in all countries. Please consult local prescribing information.
Approval code: RESP-TPE-NP-00313 Date of preparation: October 2022
- International Respiratory Coalition. Asthma 2022. Available online: https://international-respiratory-coalition.org/diseases/asthma/ (accessed October 2022)
- International Respiratory Coalition. COPD 2022 Available online: https://international-respiratory-coalition.org/diseases/copd/ (accessed October 2022)
- World Health Organization Europe 2021. Available online: https://gateway.euro.who.int/en/indicators/hfamdb_135-sdr-asthma-per-100-000/ (accessed October 2022)
- Price D, et al. NPJ Prim Care Respir Med 2014;24:14009
- Dhamane AD, et al. Int J Chron Obstruct Pulmon Dis 2015;10:2609–2618
- McDonald VM & Yorke J. Eur Resp J 2017;50:1702191
- Humenberger M, et al. BMC Pulm Med 2018;18:163
- Melani AS, et al. Respir Care 2017;62:409–414
- Chrystyn H, et al. NPJ Prim Care Respir Med 2017;27:22
- Price DB, et al. J Allergy Clin Immunol Pract 2017;5:1071–1081
- Melani AS, et al. Resp Med 2011;105:930–938
- Patel M, et al. Respirology 2013;18:546–552
Home-based pulmonary rehabilitation in a digital world05 Sep 2023
Pulmonary rehabilitation (PR) is a cornerstone of treatment for patients with chronic respiratory disease given the growing evidence of its efficacy in improving outcomes in patients with both asthma1 and COPD2. Despite this, uptake of PR has typically been low for a multitude of reasons, including the barrier of geographical distance to traditional PR delivery centres for many patients.3 While there here has been long-term interest in how telehealth might…